| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/22/2023 | 66.82% | Cantor Fitzgerald | → $2 | Reiterates | Overweight → Overweight |
| 08/15/2023 | 66.82% | Cantor Fitzgerald | → $2 | Reiterates | Overweight → Overweight |
| 06/23/2023 | 66.82% | Cantor Fitzgerald | → $2 | Reiterates | Overweight → Overweight |
| 06/23/2023 | 233.64% | Benchmark | $4 → $4 | Reiterates | Speculative Buy → Speculative Buy |
| 05/16/2023 | 66.82% | Cantor Fitzgerald | $3 → $2 | Maintains | Overweight |
| 05/15/2023 | 233.64% | BTIG | $11 → $4 | Maintains | Buy |
| 03/30/2023 | 817.51% | BTIG | → $11 | Maintains | Buy |
| 03/24/2023 | 233.64% | Benchmark | $6 → $4 | Maintains | Buy |
| 02/13/2023 | 900.92% | BTIG | $12 → $12 | Maintains | Buy |
| 04/28/2022 | 900.92% | BTIG | → $12 | Maintains | Buy |
| 03/14/2022 | 233.64% | B. Riley Securities | $6 → $4 | Maintains | Buy |
| 03/08/2022 | 150.23% | Cantor Fitzgerald | $5 → $3 | Maintains | Overweight |
| 09/27/2021 | 567.28% | Roth Capital | $2.5 → $8 | Upgrades | Neutral → Buy |
| 08/10/2021 | 108.52% | Roth Capital | $4 → $2.5 | Maintains | Neutral |
| 07/01/2021 | 567.28% | Guggenheim | → $8 | Initiates Coverage On | → Buy |
| 06/01/2021 | 734.1% | Cantor Fitzgerald | → $10 | Initiates Coverage On | → Overweight |
| 03/30/2021 | 1151.15% | B. Riley Securities | → $15 | Initiates Coverage On | → Buy |
| 03/12/2021 | 1067.74% | BTIG | → $14 | Initiates Coverage On | → Buy |
| 11/18/2019 | 66.82% | HC Wainwright & Co. | $4 → $2 | Maintains | Buy |
| 11/14/2019 | — | Benchmark | Initiates Coverage On | → Speculative Buy | |
| 05/14/2019 | — | Roth Capital | Initiates Coverage On | → Buy | |
| 05/10/2019 | 233.64% | HC Wainwright & Co. | → $4 | Initiates Coverage On | → Buy |
What is the target price for Seelos Therapeutics (SEEL)?
The latest price target for Seelos Therapeutics (NASDAQ: SEEL) was reported by Cantor Fitzgerald on August 22, 2023. The analyst firm set a price target for $2.00 expecting SEEL to rise to within 12 months (a possible 66.82% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Seelos Therapeutics (SEEL)?
The latest analyst rating for Seelos Therapeutics (NASDAQ: SEEL) was provided by Cantor Fitzgerald, and Seelos Therapeutics reiterated their overweight rating.
When is the next analyst rating going to be posted or updated for Seelos Therapeutics (SEEL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Seelos Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Seelos Therapeutics was filed on August 22, 2023 so you should expect the next rating to be made available sometime around August 22, 2024.
Is the Analyst Rating Seelos Therapeutics (SEEL) correct?
While ratings are subjective and will change, the latest Seelos Therapeutics (SEEL) rating was a reiterated with a price target of $0.00 to $2.00. The current price Seelos Therapeutics (SEEL) is trading at is $1.20, which is within the analyst's predicted range.